>2013
8e7978110.1371/journal.pone.007978124236158ButlerLMAgusDBScherHIHigginsBRoseACordon-CardoCThalerHTRifkindRAMarksPARichonVMSuberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo20006051657011016644GaupelA.CBegleyTTenniswoodMHigh throughput screening identifies modulators of histone deacetylase inhibitors20141552810.1186/1471-2164-15-52824968945WestACJohnstoneRWNew and emerging HDAC inhibitors for cancer treatment2014124303910.1172/JCI6973824382387HuangYCHuangFIMehndirattaSLaiSCLiouJPYangCRAnticancer activity of MPT0G157, a derivative of indolylbenzenesulfonamide, inhibits tumor growth and angiogenesis201561859060110.18632/oncotarget.406826087180HaKFiskusWChoiDSBhaskaraSCerchiettiLDevarajSGShahBSharmaSChangJCMelnickAMHiebertSBhallaKNHistone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells2014556375010.18632/oncotarget.215425026298YangYFiskusWYongBAtadjaPTakahashiYPanditaTKWangHGBhallaKNAcetylated HSP70 and KAP1-mediated Vps34 SUMOylation is required for autophagosome creation in autophagy201311068414610.1073/pnas.121769211023569248HaalandIOpsahlJABervenFSReikvamHFredlyHKHaugseRThiedeBMcCormackELainSBruserudOGjertsenBTMolecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia20141311610.1186/1476-4598-13-11624885082KimHJBaeSCHistone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs201131667921416059StrausDJHamlinPAMatasarMJLia PalombaMDrullinskyPRZelenetzADGerecitanoJFNoyAHamiltonAMElstromRWegnerBWortmanKCellaDPhase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation20151686637010.1111/bjh.1319525316653KirschbaumMGojoIGoldbergSLBredesonCKujawskiLAYangAMarksPFrankelPSunXTosoliniAEidJELubinieckiGMIssaJPA phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome20141671859310.1111/bjh.1301625040094GueugnonFCartronPFCharrierCBertrandPFonteneauJFGregoireMBlanquartCNew histone deacetylase inhibitors improve cisplatin antitumor properties against thoracic cancer cells2014545041510.18632/oncotarget.205624980825TuYHershmanDLBhallaKFiskusWPellegrinoCMAndreopoulouEMakowerDKalinskyKFehnKFinebergSNegassaAMontgomeryLLA phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer20141461455210.1007/s10549-014-3008-524903226HanJYLeeSHLeeGKYunTLeeYJHwangKHKimJYKimHTPhase I/II study of gefitinib (Iressa(®)) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer2015754758310.1007/s00280-014-2664-925552401SunSHanYLiuJFangYTianYZhouJMaDWuPTrichostatin A targets the mitochondrial respiratory chain, increasing mitochondrial reactive oxygen species production to trigger apoptosis in human breast cancer cells20149e9161010.1371/journal.pone.009161024626188RuefliAAAusserlechnerMJBernhardDSuttonVRTaintonKMKoflerRSmythMJJohnstoneRWThe histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell death pathway characterized by cleavage of Bid and production of reactive oxygen species200198108333811535817RosatoRRAlmenaraJAGrantSThe histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/ WAF1 120036336374512839953SarangiUSinghMKAbhijnyaKVReddyLPPrasadBSPitkeVVPaithankarKSreedharASHSP60 chaperonin acts as barrier to pharmacologically induced oxidative stress mediated apoptosis in tumour cells with differential stress response20137355110.4137/DTI.S1251324027419FiskusWRenYMohapatraABaliPMandawatARaoRHergerBYangYAtadjaPWuJBhallaKHydroxamic Acid Analogue Histone Deacetylase Inhibitors Attenuate Estrogen Receptor-A Levels and Transcriptional Activity: A Result of Hyperacetylation and Inhibition of Chaperone Function of Heat Shock Protein 9020071348829017699868RadiRProtein tyrosine nitration: biochemical mechanisms and structural basis of its functional effects2013465505910.1021/ar300234c23157446CampanellaCCaruso BavisottoCMarino GammazzaANikolicDRappaFDavidSCappelloFBucchieriFFaisSExosomal heat shock proteins as new players in tumour cell-to-cell communication20143510.5772/58721JohnstoneRMExosomes biological significance: A concise review2006363152116487731CornagoMGarcia-AlberichCBlasco-AnguloNVall-LlauraNNagerMHerrerosJComellaJXSanchisDLloveraMHistone deacetylase inhibitors promote glioma cell death by G2 checkpoint abrogation leading to mitotic catastrophe20145e143510.1038/cddis.2014.41225275596XuXD